Scott Kopetz, MD, PhD, FACP, provides advice on the management of patients with BRAFV600E-mutant metastatic colorectal cancer with the triplet regimen of encorafenib, binimetinib, and cetuximab, a regimen studied in the BEACON and ANCHOR trials.
Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities
Telephone-Based Weight Loss Program Is Effective for Breast Cancer Survivors
Pembrolizumab Plus Chemo With or Without Bevacizumab Maintains OS Benefit in Frontline Cervical Cancer
Minimally Invasive Distal Pancreatectomy Provides Effective Alternative in Resectable Pancreatic Cancer